Early dose/received it twice, 26 days apart; This non-serious case was reported by a other health professional via call center representative and described the occurrence of drug dose administration interval too short in a 16-year-old patient who received Men B NVS (Bexsero) (batch number 4L274, expiry date 30-SEP-2024) for prophylaxis. Concomitant products included Meningococcal vaccine B rfHbp/NadA/NHBA OMV (Bexsero). On 08-FEB-2024, the patient received the 2nd dose of Bexsero. On 08-FEB-2024, an unknown time after receiving Bexsero, the patient experienced drug dose administration interval too short (Verbatim: Early dose/received it twice, 26 days apart). The outcome of the drug dose administration interval too short was unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 13-JAN-2025 The other health professional had a question about somebody who received the Bexsero vaccine. The other health professional reported that it was a meningitis b Bexsero vaccine, and then there was a question about, he/she know that it was recently updated, the guidance was recently updated for the first and second dose being 6 months but last in January and February of 2024 a patient received it twice, 26 days apart. The other health professional just wanted to know does the patient need to be revaccinated or what was recommended. The patient received second dose of Bexsero shorter than the recommended interval which led to shortening of vaccination schedule.